Home Technology FINN Partners releases new whitepaper highlighting challenges for scaling the UK and European biotech and biopharma industry
Technology

FINN Partners releases new whitepaper highlighting challenges for scaling the UK and European biotech and biopharma industry

Share


  • Whitepaper released as part of London Life Sciences Week explores what is needed to overcome the challenges facing biotech and biopharma in the UK and Europe.

  • FINN Partners sets out the playbook on the role of communications in overcoming the most pressing challenges.

LONDON, Nov. 16, 2026 /PRNewswire/ — Global independent marketing and communications firm FINN Partners has released a landmark whitepaper The Future of Biotech and Biopharma in the UK & Europe, published to coincide with London Life Sciences Week 2026.

FINN Partners logo
FINN Partners logo

The whitepaper analyses the structural barriers standing in the way of UK and continental European life science companies from becoming globally dominant market players.

Sophie Taylor-Roberts, managing partner and UK health lead, FINN Partners, said: “UK and European life sciences ecosystems generate world-class innovations, but as we know scientific excellence is not enough on its own to guarantee commercial success. To redress the balance, we need to eliminate the transatlantic scaling gap.”

“As investors and life sciences leaders meet at London Life Sciences Week, our whitepaper examines the impact of cross-border manufacturing bottlenecks, addresses the realities of NHS and single-payer reimbursement, and provides a framework for what needs to be done to ensure the future success of the industry in the UK and Europe.”

The whitepaper looks specifically at the problem of transatlantic capital deficiency and scaling, overcoming post-Brexit difficulties in manufacturing of the product due to CDMO logistics, and addressing health technology assessments (HTAs) in the UK and European single-payer markets. It also focusses on mitigating the risks related to health data security in the era of generative artificial intelligence and machine learning technologies.

Highlights of the whitepaper include:

How to surmount structural growth challenges: Though the “Golden Triangle” of the UK (Oxford, Cambridge, London) and research clusters in Europe including BioRN, Basel and Medicon Valley generate world-class scientific research, there are often difficulties with growth financing and lab space shortages. The whitepaper suggests creating a “connected density” across Europe to establish an efficient ecosystem of capital, talent and fluid infrastructure.

Fortifying supply chain resilience and mitigating reputational damage: Biopharma often suffers from severe supply chain risks due to high customs barriers related to post-Brexit cross-border manufacturing. The whitepaper explores how supply chain and cold-chain resilience and local CDMO partnerships could be used as key commercial differentiators in the field.



Source link

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Articles
Technology

Digital-only banks could be forced to fund high street banking | Banking

Digital banks like Monzo and Revolut could be forced to pay towards...

Technology

Top 3 British Biotech Stocks To Watch In November 2026

Rising wholesale inflation in the US and expectations of further rate hikes...

Technology

Morrisons becomes first UK supermarket to introduce ‘flashing’ shelf change

No more scanning the aisles for one product.Morrisons is rolling out convenient...

Technology

NCSC warns UK businesses of scams following Microsoft outage

Photo: wachiwit / stock.adobe.com The UK’s National Cyber Security Centre (NCSC) has...